Drug Interaction Studies with Dexlansoprazole Modified Release (TAK-390MR), a Proton Pump Inhibitor with a Dual Delayed-Release Formulation Results of Four Randomized, Double-Blind, Crossover, Placebo-Controlled, Single-Centre Studies

• Published in: Clinical drug investigation Vol. 29; no. 1; pp. 35 - 50
• Main Authors: Vakily, Majid, Lee, Ronald D., Wu, Jingtao, Gunawardhana, Lhanoo, Mulford, Darcy
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.01.2009; Springer Nature B.V
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage; 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics; Adult; Anticoagulants - administration & dosage; Anticoagulants - pharmacokinetics; Anticonvulsants - administration & dosage; Anticonvulsants - pharmacokinetics; Area Under Curve; Aryl Hydrocarbon Hydroxylases - metabolism; Bronchodilator Agents - administration & dosage; Bronchodilator Agents - pharmacokinetics; Cross-Over Studies; Delayed-Action Preparations; Dexlansoprazole; Diazepam - administration & dosage; Diazepam - pharmacokinetics; Double-Blind Method; Drug Interactions; Female; Humans; Internal Medicine; Lansoprazole; Male; Medicine & Public Health; Middle Aged; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Phenytoin - administration & dosage; Phenytoin - pharmacokinetics; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - pharmacokinetics; Theophylline - administration & dosage; Theophylline - pharmacokinetics; Warfarin - administration & dosage; Warfarin - pharmacokinetics; Young Adult; Omeprazole; International Normalize Ratio; Warfarin; Theophylline; Lansoprazole

Background and objective: Most proton pump inhibitors are extensively metabolized by cytochrome P450 (CYP) isoenzymes, as are many other drugs, giving rise to potential drug-drug interactions. Dexlansoprazole modified release (MR) [TAK-390MR] is a modified-release formulation of dexlansoprazole (TAK...